Healthcare provider profile · identity verified

Harpreet Singh, M.D.

Allopathic & Osteopathic Physicians|Family Medicine · PLACERVILLE, CA · NPI 1760862437

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Harpreet Singh, M.D. received $104.51 in general payments during 2025 across 1 reported records.

ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$104.51

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) Unresolved — no canonical attribution shown $104.51100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$104.511

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
LifeVest
Normalized: lifevest
Device ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $104.51 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium29370
LisinoprilLisinopril17444
Amlodipine BesylateAmlodipine Besylate16531
GabapentinGabapentin15130
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14528
Albuterol Sulfate HfaAlbuterol Sulfate13038
Levothyroxine SodiumLevothyroxine Sodium12628
Sertraline HclSertraline Hcl11612
OmeprazoleOmeprazole9718
Tamsulosin HclTamsulosin Hcl9626
Losartan PotassiumLosartan Potassium9218
BaclofenBaclofen8524
Quetiapine FumarateQuetiapine Fumarate78suppressed
Metformin HclMetformin Hcl7717
Escitalopram OxalateEscitalopram Oxalate7514
FamotidineFamotidine7421
Pantoprazole SodiumPantoprazole Sodium7313
ClopidogrelClopidogrel Bisulfate69suppressed
EliquisApixaban6812
SimvastatinSimvastatin6616
MeloxicamMeloxicam6518
Duloxetine HclDuloxetine Hcl62suppressed
CarvedilolCarvedilol52suppressed
Diclofenac SodiumDiclofenac Sodium5017
PregabalinPregabalin50suppressed
Metoprolol SuccinateMetoprolol Succinate4813
Cyclobenzaprine HclCyclobenzaprine Hcl4412
Fluticasone PropionateFluticasone Propionate4417
Trazodone HclTrazodone Hcl4412
AtenololAtenolol43suppressed
Montelukast SodiumMontelukast Sodium43suppressed
Hydroxyzine HclHydroxyzine Hcl4217
Potassium ChloridePotassium Chloride41suppressed
FurosemideFurosemide3711
Alendronate SodiumAlendronate Sodium34suppressed
Bupropion XlBupropion Hcl32suppressed
HydrochlorothiazideHydrochlorothiazide3211
MirtazapineMirtazapine31suppressed
Metoprolol TartrateMetoprolol Tartrate30suppressed
NaproxenNaproxen2912
Citalopram HbrCitalopram Hydrobromide27suppressed
IbuprofenIbuprofen27suppressed
SynthroidLevothyroxine Sodium25suppressed
Bupropion Hcl SrBupropion Hcl24suppressed
Advair HfaFluticasone Propion/Salmeterol23suppressed
Oxybutynin Chloride ErOxybutynin Chloride23suppressed
Oxycodone HclOxycodone Hcl23suppressed
AlprazolamAlprazolam21suppressed
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide21suppressed
Buspirone HclBuspirone Hcl20suppressed
JardianceEmpagliflozin20suppressed
IndomethacinIndomethacin19suppressed
Sumatriptan SuccinateSumatriptan Succinate18suppressed
Fluoxetine HclFluoxetine Hcl17suppressed
Hydralazine HclHydralazine Hcl17suppressed
Pravastatin SodiumPravastatin Sodium17suppressed
FinasterideFinasteride16suppressed
LamotrigineLamotrigine16suppressed
MethocarbamolMethocarbamol16suppressed
Ondansetron HclOndansetron Hcl16suppressed
TopiramateTopiramate16suppressed
Venlafaxine Hcl ErVenlafaxine Hcl16suppressed
Wixela InhubFluticasone Propion/Salmeterol16suppressed
FarxigaDapagliflozin Propanediol15suppressed
Amitriptyline HclAmitriptyline Hcl14suppressed
BreynaBudesonide/Formoterol Fumarate13suppressed
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst1312
Oxybutynin ChlorideOxybutynin Chloride13suppressed
Paroxetine HclParoxetine Hcl13suppressed
PerphenazinePerphenazine13suppressed
Ventolin HfaAlbuterol Sulfate13suppressed
Atrovent HfaIpratropium Bromide12suppressed
Breo ElliptaFluticasone/Vilanterol12suppressed
GlimepirideGlimepiride12suppressed
LorazepamLorazepam12suppressed
Rosuvastatin CalciumRosuvastatin Calcium12suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12suppressed
Incruse ElliptaUmeclidinium Bromide11suppressed
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm11suppressed
NystatinNystatin11suppressed
Pramipexole DihydrochloridePramipexole Di-Hcl11suppressed
PrednisonePrednisone1111
SpironolactoneSpironolactone11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $104.51 · 1 records ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) LifeVest
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error